Full Year 2024 Results Key Financial Results Net loss: US$59.6m (loss narrowed ...

BofA analyst Alec Stranahan lowered the firm’s price target on BioXcel Therapeutics (BTAI) to $1 from $4 and keeps an Underperform rating on ...

Reports Q4 revenue $366k, consensus $718.26k. “We believe that our SERENITY program presents an exciting opportunity to address a substantial ...

Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 ...

The Chattogram City Corporation (CCC) has begun an experimental deployment of Bacillus thuringiensis israelensis (BTI), a ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) was the target of a significant increase in short interest in the ...

Artificial Intelligence (AI) and Machine Learning (ML) play a pivotal role in precision oncology, analyzing vast datasets, ...

He joins MindMed from BioXcel Therapeutics, where he served as CCO overseeing the launch of the company’s first acute treatment of agitation associated with schizophrenia and bipolar disorder. Prior ...

We recently compiled a list of the 10 Micro-, Small-Cap Firms Were Last Week's Top Performers. In this article, we are going to take a look at where BioXcel Therapeutics, Inc. (NASDAQ:BTAI) stands ...

In this article, we are going to take a look at where BioXcel Therapeutics, Inc. (NASDAQ:BTAI) stands against the other stocks. Micro- and small-cap companies dominated the stock market last week ...

BioXcel’s share price increased by 56 percent week-on-week to finish Friday at $3.37 from $2.16 on February 28 as investor sentiment was largely boosted by news that it has achieved a 33-percent ...